The nContact CONVERGE Trial Will Study the Convergent Procedure for Treatment of Persistent Atrial Fibrillation
nContact has launched the CONVERGE clinical trial to compare the Convergent Procedure with catheter ablation for treating persistent afib
By Mellanie True Hills and Melissa Moss
June 26, 2014
- Summary: The CONVERGE trial will study the convergent procedure for persistent atrial fibrillation.
- Reading time: 1–2 minutes
nContact has launched the CONVERGE (Convergence Of Epicardial And Endocardial Radiofrequency Ablation For The Treatment Of Symptomatic Persistent AF) study for treatment of persistent atrial fibrillation. This trial will compare the convergent procedure with traditional catheter ablation.
The Convergent Procedure combines surgery and catheter ablation in a single procedure in a single setting. The minimally-invasive surgical procedure works on the outside of the heart, and accesses it through a small abdominal incision.
To learn more about the study, including who is eligible and what centers are participating, see:
- The Convergent Procedure: The CONVERGE IDE Clinical Trial, EP Lab Digest, May, 2014